# Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

> **NCT00802841** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 191 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** nilotinib
- **DRUG:** imatinib

## Key facts

- **NCT ID:** NCT00802841
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2015-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802841, "Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00802841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*